Leadership Team

Managing Partner - Valletta, Malta

Christophe Fabregue is Founder and Managing Partner of HYPERION Life Sciences, M&A and licensing advisory company.

Background: More than 10 years of experience in the pharmaceutical industry: French Drug Regulatory Agency and pharmaceutical companies (Pfizer, Aventis Pharma, Bristol-Myers Squibb); 17 years in M&A-Business development consulting

Network: Executive committee of Pharma Licensing Club France (PLCF) from 2006 to 2012, and active member of the European Pharma Licensing Club (EPLC) and PLG UK

Teaching: Head of «M&A, Business Development & Licensing» courses in top French business school: ESCP Europe (Master in pharmaceutical management)

Education: MS Economics, and BA - Institut d’Etudes Politiques; Sorbonne University; ESCP Europe Business School; Corporate Finance Strategy program – Insead

Core competencies: Divestitures – Acquisitions – Licensing

Senior Advisor - Lisbon, Portugal

Antoine Ortoli is Senior Advisor of Hyperion Life Sciences.

Background: 33 years at Sanofi as top executive:

• CFO of the Pharma Division
• General Manager in Europe
• VP for Latin America
• VP Africa-Middle East, Eastern Countries and Asia
• Senior VP for Intercontinental region (90 countries; 12 billion euros sales)
• Chairman of the Strategic Emerging Markets Committee

Core Competences and M&A credentials: Business Strategy and Marketing, BD & Alliances, Integration-Restructuring. Antoine was closely involved in global Acquisitions and Alliances (Sterling Winthrop, BMS, Synthelabo, Aventis) and conducted many local acquisitions in LATAM: Brazil (Medley), Argentina (Gramon), Colombia (Genfar), Mexico (Kendrick), Chili.

Education: Neoma business school (1976); Chartered accountant (1980); Insead (AMP 93).

Senior Advisor - Paris, France

Claude Perol is Senior Advisor of HYPERION Life Sciences. He has an in-depth experience of international pharma industry of more than 30 years.

Background: He worked mainly at Sanofi as top executive through different leadership positions:

• Head of Established Products Franchise (10 billion euros; 2014-2016)
• VP Central & Eastern Europe (1.5 billion euros; 2007-2014)
• Head of Business Excellence Pharma (2000-2005)
• Head of Generic Division (1993-1999)
• Health Strategy Head at Elf group (1989-1993)
• Leader of the Hepatitis B Jventure in Taiwan (1984-1987)

Education: Doctor in Pharmacy; MBA Insead (1982)

Partner USA - New Jersey

Stéphane Berthier joined Hyperion Life Sciences as Partner in 2026.

Background: Stéphane is a biopharmaceutical executive and company builder with over 25 years of international leadership across research and development, commercialization, and corporate strategy in oncology, hematology, and rare diseases. He has a proven record of creating enterprise value across the drug development lifecycle, from early scientific strategy through late-stage development, commercialization, and strategic transactions. He has led complex corporate development initiatives, including licensing, strategic partnerships, asset acquisitions, and mergers and acquisitions preparation, aligning scientific innovation with commercial and financial outcomes. His experience spans small molecules, biologics, and cell and gene therapies, supported by deep expertise in regulatory pathways, market access, and global commercialization. He spent two decades at Novartis and Johnson and Johnson, has worked in biotechnology since 2019, and founded SDK Therapeutics, a hematology-focused biotechnology company, in 2024.

Education: PharmD (Doctor of Pharmacy), University René Descartes, Paris, France (1997); Executive MBA, Lancaster University, UK (2006).

Partner Americas

Juan Carlos joined Hyperion Life Sciences as Partner in 2026 to execute corporate development assignments.

Background: With over 25 years of leadership in the Life Sciences and Social Impact sectors, Juan Carlos brings a wealth of experience in high-level financial strategy and global operations. He has a proven track record of orchestrating complex cross-border transactions, including successful public offerings and high-value corporate exits. His expertise lies in navigating intricate regulatory landscapes and optimizing organizational structures to drive sustainable growth and investor value.

His professional background spans a wide range of therapeutic areas, including neuroscience—specifically Alzheimer's and Parkinson's disease—as well as immunology, oncology, vaccines, and plasma-derived therapies. He has successfully navigated diverse market segments, ranging from therapeutics and drug development to early diagnostics and health-focused technology platforms. In addition to his background in M&A, he specializes in the strategic management of IP and technology licensing. Having served as both a founder and a CEO, he offers a unique perspective that bridges scientific innovation with private capital.

Project Manager - Kobe, Japan

Michel Mertz joined Hyperion in 2021 as a Project Manager to support Licensing and M&A projects.

Education: He graduated in 2019 from The École Supérieure de Biotechnologie de Strasbourg, a trinational school shared between the Universities of Strasbourg (FR), Basel (CH) and Freiburg (DE), with both an Engineer's degree in Biotechnology and a Master's in High-Throughput Analysis obtained the same year. He then graduated from the ESCP Business School's MBA program in Biopharmaceutical Management to complete his scientific background with business and finance skills.

Michel can fluently speak French, Spanish, English and possesses a JLPT N2 level in Japanese.